Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.

Two experts discuss why more research is needed before continuous glucose monitors can be used reliably for insulin ...

Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits ...

Abbott's mixed reality technology helps distract blood donors and reduce their anxiety levels. This can help encourage young ...

The global continuous glucose monitoring device market is estimated to be valued at USD 12,690.7 million in 2025 and is projected to reach USD 54,553.1 million by 2035, registering a CAGR of 15.7% ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before.

CGM devices like FreeStyle Libre offer real-time glucose readings, helping you stay within your target range and reduce the risk of long-term complications. With the right tools, you can manage your ...

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott's new head of diabetes business.

Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.

Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory. Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. Abbott is ...

DexCom DXCM delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and meaningful progress in its long-term strategic initiatives. As the year ...